Clinical trials: Anticoagulant
Atrial Fibrillation
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) and with anti vitamin K (VKA)…
- Trial name
- PRESAGE-ACO (NCT02286414)
- Testing
- Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban, Vitamin K antagonist: warfarin, fluindione, acenocoumarol
- Where
- France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Polyp of Colon
Prevention of Post-Polypectomy Colorectal Bleeding by Clips in Patients on Anticoagulants
This observational study aims to retrospectively determine if clips can prevent post-polypectomy bleeding in adults who have received restarted anticoagulants after a colorectal polypectomy, using a large, single-center patient…
- Trial name
- PiCAnt (NCT07007598)
- Testing
- Hemostatic clip
- Where
- Germany
- Volunteers
- 10,000 people
- Sponsor
- Helios Kliniken Schwerin
COVID-19 Patients
Assessment of the Natural Anticoagulant Profile in Patients With COVID-19
At the beginning of 2020, coronavirus disease 19 (COVID-19) was declared a pandemic of international concern and an unprecedented challenge for country-specific health care systems .
- Trial name
- NCT05083104
- Testing
- laboratory investigations on coagulation profiles
- Volunteers
- 50 people
- Sponsor
- Sohag University
LVAD (Left Ventricular Assist Device) Thrombosis
DOT HeartMate 3 Study
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
- Trial name
- NCT04974684
- Testing
- HeartMate 3, Apixaban
- Where
- Czechia
- Volunteers
- 45 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Embolism and Thrombosis, Hemorrhage
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs).
- Trial name
- ADR-OAC (NCT02720328)
- Testing
- Blood samples for DOAC measurement
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Benign Prostatic Hyperplasia, Postoperative Hemorrhage
Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation.
A prospective, randomized, double-blinded controlled trial to evaluate the efficacy of a 2-week preoperative and 2-week postoperative course of oral dutasteride (0.5 mg daily) in reducing perioperative blood loss, irrigation…
- Conditions
- Benign Prostatic Hyperplasia, Postoperative Hemorrhage, Perioperative Hemorrhage Control During Bipolar Transurethral Resection of the Prostate (TURP) in Patients on Anticoagulant or Antiplatelet Therapy
- Trial name
- DUT-TURP (NCT07911501)
- Testing
- Dutasteride (0.5mg)
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Mohamed Mahmoud Dogha
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Atrial Fibrillation, Stroke
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as…
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Trial name
- NCT00403767
- Testing
- Rivaroxaban, Warfarin
- Where
- 932 sites in United States, Argentina and 42 more
- Volunteers
- 14,269 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Health Education, Patient Education as Topic
Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study)
Background: Oral anticoagulant drugs represent an essential tool in thrombo-embolic events prevention. Most used are vitamin K antagonists (VKA), which plasma level is monitored measuring prothrombin time using the International…
- Conditions
- Health Education, Patient Education as Topic, Blood Coagulation Tests
- Trial name
- TAOPE (NCT03647254)
- Testing
- Patient education group
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Francisco Javier Navarro Moya
Auricular Fibrillation, Anticoagulant Drugs
Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year
- Trial name
- NCT04133545
- Where
- Argentina
- Volunteers
- 360 people
- Sponsor
- Hospital Italiano de Buenos Aires
Antithrombotic Agents
Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department
Antithrombotics with antiplatelet agents, vitamin K antagonist (VKA), heparin and related substances, and new oral anticoagulants are prescribed for arterial diseases, especially in secondary prevention of embolic disease in…
- Trial name
- RATED Registry (NCT02706080)
- Testing
- emergency
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Clermont-Ferrand
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Atrial Fibrillation
Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter
A study for subjects with atrial fibrillation (AF) or atrial flutter who are diagnosed with left atrial (LA) or left atrial appendage (LAA) thrombus. The study will assign subjects to rivaroxaban for treatment of thrombi.
- Trial name
- X-TRA (NCT01839357)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 31 sites in Bulgaria, France and 5 more
- Volunteers
- 60 people
- Sponsor
- Bayer
Atrial Fibrillation
Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04593056
- Testing
- Warfarin, Rivaroxaban
- Where
- United States
- Volunteers
- 102,636 people
- Sponsor
- Brigham and Women's Hospital
Stroke, Cerebrovascular Stroke
Addressing Real-world Anticoagulant Management Issues in Stroke
The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in…
- Conditions
- Stroke, Cerebrovascular Stroke, Intracerebral Hemorrhage
- Trial name
- ARAMIS (NCT02478177)
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- Duke University
Atrial Fibrillation
Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding…
- Trial name
- NCT02504177
- Testing
- novel oral anticoagulant for 30 days, novel oral anticoagulant for 24 hour
- Where
- South Korea
- Volunteers
- 433 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Comparison of Heparin Types; Efficacy and Safety
Heparin, a blood thinner, is used routinely in Open-heart surgery. Do different brands of this drug have differing clinical effects despite both having exactly the same regulation and marketing specifications?
- Trial name
- NCT01343381
- Testing
- Hepalean Heparin, PPC Heparin
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- McMaster University
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease
The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e.
- Trial name
- PRODOAC (NCT06239402)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 394 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Coagulation Disorder
Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts: Part 1: Single dose of…
- Trial name
- NCT06372483
- Testing
- VMX-C001, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.